PDS Biotechnology Misses Q1 EPS by 10c
- ByInvesting.com-
PDS Biotechnology (NASDAQ:PDSB) reported Q1 EPS of ($0.32), $0.10 worse than the analyst estimate of ($0.22).
PDS Biotechnology (NASDAQ:PDSB) reported Q1 EPS of ($0.32), $0.10 worse than the analyst estimate of ($0.22).
Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Consumer Goods, Technology and Consumer Services sectors led shares lower. At the close in...
Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Healthcare, Technology and Utilities sectors led shares higher while losses in the Basic...
Every investor wants to buy into a stock that’s primed for growth. The trick in successful investing is finding those stocks. What makes this difficult is the truth of the...
1. The Boeing CompanyBoeing (NYSE:BA), on the 737 MAX testing on Monday, popped out of a wedge and jumped 24.48, or 14.4%, to 194.49, just a penny off the session high at 194.50,...
It was a week that saw Edge Therapeutics crashing on news of discontinuation of its phase III study, Amgen’s Blincyto getting FDA’s nod for label expansion, EMA...
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is focused on developing a growing pipeline of cancer immunotherapy candidates and infectious disease vaccine candidates designed to overcome the limitations of immunotherapy technologies. It owns Versamune, a T-cell activating platform designed to train the immune system to destroy disease. Its lead product candidate, PDS0101, which combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products is all administered by subcutaneous injection. DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on agonist antigens from the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Strong Buy | Strong Buy | Neutral | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 112.60 | 113.44 | 111.56 | -0.41 | -0.36% | 5.63M | NYSE | |||
| 86.48 | 89.08 | 86.34 | -1.51 | -1.72% | 19.56M | NYSE | |||
| 94.24 | 98.17 | 93.08 | -0.88 | -0.93% | 130.55M | NASDAQ | |||
| 74.63 | 75.40 | 73.73 | -0.42 | -0.56% | 6.51M | NYSE | |||
| 3.41 | 3.77 | 3.04 | +0.44 | +14.81% | 30.69M | NASDAQ | |||
| 175.47 | 176.30 | 173.42 | +1.75 | +1.01% | 5.29M | NASDAQ | |||
| 25.96 | 26.50 | 25.77 | -0.54 | -2.04% | 2.14M | NYSE | |||
| 16.86 | 17.08 | 16.69 | -0.21 | -1.23% | 658.08K | NYSE | |||
| 95.04 | 96.13 | 94.86 | -0.36 | -0.38% | 1.64M | NYSE | |||
| 336.45 | 340.20 | 330.72 | -4.49 | -1.32% | 370.80K | NYSE | |||
| 140.08 | 152.92 | 139.73 | -13.15 | -8.58% | 2.38M | NASDAQ | |||
| 23.93 | 24.35 | 23.69 | -0.02 | -0.08% | 7.64M | NASDAQ | |||
| 29.54 | 30.40 | 28.67 | +1.19 | +4.20% | 2.27M | NYSE | |||
| 24.30 | 25.72 | 24.11 | -0.10 | -0.41% | 14.53M | NYSE | |||
| 489.22 | 495.56 | 484.15 | +3.82 | +0.79% | 2.33M | NYSE |